Tissue Factor Pathway Inhibitor-2 gene methylation is associated with low expression in carotid atherosclerotic plaques

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages

  Zawadzki, Christophe ^a,b   Chatelain, Nicolas ^a,b   Delestre, Marianne ^a   Susen, Sophie ^a,b   Quesnel, Bruno ^b   Juthier, Francis ^a,b   Jeanpierre, Emmanuelle ^a,b   Azzaoui, Richard ^b   Corseaux, Delphine ^a,b   Breyne, Joke ^a   Torpier, Gérard ^c   Staels, Bart ^c   Van Belle, Eric ^a,b   Jude, Brigitte ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Gene methylation; Tissue Factor Pathway Inhibitor 2

Indexed keywords

PLACENTA PROTEIN 5;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; TUNICA MEDIA;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; ENDARTERECTOMY, CAROTID; FEMALE; GENOTYPE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHENOTYPE; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 67349234989     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.10.009     Document Type: Article

References (41)

1. Chand H.S., Foster D.C., and Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost 94 (2005) 1122-1130
2. Petersen L.C., Sprecher C.A., Foster D.C., et al. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 35 (1996) 266-272
3. Konduri S.D., Tasiou A., Chandrasekar N., and Rao J.S. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 18 (2001) 127-131
4. Konduri S.D., Tasiou A., Chandrasekar N., Nicolson G.L., and Rao J.S. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 18 (2000) 303-308
5. Kamei S., Petersen L.C., Sprecher C.A., Foster D.C., and Kisiel W. Inhibitory properties of human recombinant Arg24-->Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2). Thromb Res 94 (1999) 147-152
6. Crawley J.T., Goulding D.A., Ferreira V., Severs N.J., and Lupu F. Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 22 (2002) 218-224
7. Herman M.P., Sukhova G.K., Kisiel W., et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 107 (2001) 1117-1126
8. Blindt R., Vogt F., Lamby D., et al. Characterization of differential gene expression in quiescent and invasive human arterial smooth muscle cells. J Vasc Res 39 (2002) 340-352
9. Dollery C.M., and Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 69 (2006) 625-635
10. Hube F., Reverdiau P., Iochmann S., Cherpi-Antar C., and Gruel Y. Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. Thromb Res 109 (2003) 207-215
11. Kamei S., Kazama Y., Kuijper J.L., Foster D.C., and Kisiel W. Genomic structure and promoter activity of the human tissue factor pathway inhibitor-2 gene. Biochim Biophys Acta 1517 (2001) 430-435
12. Bird A. The essentials of DNA methylation. Cell 70 (1992) 5-8
13. Sprecher C.A., Kisiel W., Mathewes S., and Foster D.C. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 91 (1994) 3353-3357
14. Klose R.J., and Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31 (2006) 89-97
15. Guo H., Lin Y., Zhang H., et al. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 8 (2007) 110
16. Wong C.M., Ng Y.L., Lee J.M., et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45 (2007) 1129-1138
17. Hube F., Reverdiau P., Iochmann S., et al. Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells. Biol Chem 384 (2003) 1029-1034
18. Konduri S.D., Srivenugopal K.S., Yanamandra N., et al. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene 22 (2003) 4509-4516
19. Barnett H.J., Taylor D.W., Eliasziw M., et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 339 (1998) 1415-1425
20. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92 (1995) 1355-1374
21. Walsh J.D., and Geczy C.L. Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb Haemost 66 (1991) 552-558
22. Jude B., Susen S., Flan B., et al. Detection of monocyte tissue factor after endotoxin stimulation: comparison of one functional and three immunological methods. Thromb Res 79 (1995) 65-72
23. Zawadzki C., Susen S., Richard F., et al. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins. Atherosclerosis 195 (2007) e117-e125
24. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
25. Ronaghi M., Uhlen M., and Nyren P. A sequencing method based on real-time pyrophosphate. Science 281 (1998) 363 365
26. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., and Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21 (1978) 274-281
27. Bieche I., Onody P., Laurendeau I., et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45 (1999) 1148-1156
28. Lin X.H., Guo C., Gu L.J., and Deuel T.F. Site-specific methylation inhibits transcriptional activity of platelet-derived growth factor A-chain promoter. J Biol Chem 268 (1993) 17334-17340
29. Sato N., Maehara N., Su G.H., and Goggins M. Effects of 5-aza-2′-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95 (2003) 327-330
30. White G.P., Watt P.M., Holt B.J., and Holt P.G. Differential patterns of methylation of the IFN-gamma promoter at CpG and non-CpG sites underlie differences in IFN-gamma gene expression between human neonatal and adult CD45RO- T cells. J Immunol 168 (2002) 2820-2827
31. Tanaka Y., Fukudome K., Hayashi M., Takagi S., and Yoshie O. Induction of ICAM-1 and LFA-3 by Tax1 of human T-cell leukemia virus type 1 and mechanism of down-regulation of ICAM-1 or LFA-1 in adult-T-cell-leukemia cell lines. Int J Cancer 60 (1995) 554-561
32. Wild A., Ramaswamy A., Langer P., et al. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab 88 (2003) 1367-1373
33. Post W.S., Goldschmidt-Clermont P.J., Wilhide C.C., et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 43 (1999) 985-991
34. Rao C.N., Segawa T., Navari J.R., et al. Methylation of TFPI-2 gene is not the sole cause of its silencing. Int J Oncol 22 (2003) 843-848
35. Rollin J., Iochmann S., Blechet C., et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 92 (2005) 775-783
36. Sato N., Parker A.R., Fukushima N., et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24 (2005) 850-858
37. Jiang Y., Jiang J., Xiong J., et al. Homocysteine-induced extracellular superoxide dismutase and its epigenetic mechanisms in monocytes. J Exp Biol 211 (2008) 911-920
38. Nile C.J., Read R.C., Akil M., Duff G.W., and Wilson A.G. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 58 (2008) 2686-2693
39. Yi-Deng J., Tao S., Hui-Ping Z., et al. Folate and ApoE DNA methylation induced by homocysteine in human monocytes. DNA Cell Biol 26 (2007) 737-744
40. Lund G., Andersson L., Lauria M., et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem 279 (2004) 29147-29154
41. Higashikata T., Yamagishi M., Higashi T., et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis (2006)